Hologic is sponsoring the "HPV-Testing out of the ThinPrep PreservCyt Vial:  Customer Experiences and Automation Solutions" symposium on Monday September 19th from 17.30 to 18.30 at the IPV meeting.  The symposium is open to anyone attending the conference.  Over 1,000 conference attendees are expected to attend.  

Research on human papillomaviruses has made impressive progress in recent years.  Better diagnosis and therapies have helped to significantly reduce the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV.  However, next to breast cancer, cervical carcinoma remains the second most frequent cancer affecting women worldwide.  The IPV meeting and workshop is the major international conference that encompasses all aspects of HPV research.  Hologic is a gold sponsor of the event.

SOURCE Hologic, Inc.